# Tesamorelin

> GHRH analog FDA-approved for HIV-associated visceral fat.

Source: https://peptides.cafe/peptide/tesamorelin
Category: Growth Hormone Axis
Tag: Body composition

## Mechanism
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.

## Research areas
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)

## Common research protocols
- Daily subcutaneous clinical use: 2 mg subcutaneous daily in the approved HIV-lipodystrophy indication.

## Study summaries
- "Tesamorelin for HIV-associated lipodystrophy" — New England Journal of Medicine (2007): Phase 3 trials showing significant visceral fat reduction.
- "Tesamorelin and NAFLD in HIV" — The Lancet HIV (2019): Reduced hepatic fat fraction in HIV-infected adults with NAFLD.

## Considerations
- FDA-approved only for HIV-associated lipodystrophy.
- May affect glucose tolerance; monitor in at-risk patients.
- Requires physician oversight.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.